- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04910789
Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction
A Prospective, Multicenter, Randomized, Controlled Study Comparing Surgical Efficacy Between Transhiatal/Transabdominal and Thoracoabdominal Approach for Patients With Siewert II Adenocarcinoma of Esophagogastric Junction
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Objective: To compare the safety and clinical efficacy between transhiatal/transabdominal and thoracoabdominal approach for Siewert Ⅱ adenocarcinoma of esophagogastric junction.
Methods: A prospective, multi-center, randomized, controlled study will be performed. Patients who meet the eligibility criteria will be registered in the study and undergo radical surgery via transhiatal/transabdominal or thoracoabdominal approach. The data of preoperative, intraoperative, postoperative and follow-up will be recorded and analyzed.
The primary endpoints :3-year disease-free survival. The secondary endpoints:(1) Surgery and oncology indicators ;(2) The incidences of postoperative complications and mortality.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Xinxin Wang, Dr
- Telefonnummer: +8613811858199
- E-mail: 301wxx@sina.com
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100853
- Rekruttering
- Chinese PLA General Hospital
-
Kontakt:
- Xinxin Wang, Dr.
- Telefonnummer: +8613811858199
- E-mail: 301wxx@sina.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 1.18~75 years old
- 2.The tumor center located at the esophagogastric junction(EGJ) line from 1cm above to 2cm below(SiewertⅡ) .
- 3.Histological diagnosis of adenocarcinoma
- 4. American Society of Anesthesiologists(ASA) physical status class is less than or equal to 3
- 5.Informed consent of patients
Exclusion Criteria:
- 1.Patients with distant metastasis (M1) or invasion of surrounding organs
- 2.History of esophagectomy and gastrectomy (including endoscopic mucosal resection/endoscopic submucosal dissection for gastric cancer and esophageal cancer)
- 3.History of other malignant tumors within 5 years
- 4.The researcher believes that the patient is not suitable to participate in the clinical trial
- 5.Patients who persist in withdrawing from clinical trials
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Thoracoabdominal approach
Radical surgery should be finished via Thoracoabdominal approach.
|
Radical surgery should be finished via thoracoabdominal approach
|
Aktiv komparator: Transhiatal/transabdominal approach
Radical surgery should be finished via transhiatal/transabdominal approach.
|
Radical surgery should be finished via transhiatal/transabdominal approach
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
3-year disease-free survival
Tidsramme: 3 years after surgery
|
Proportion of patients without tumor recurrence from surgery to the end of the 3-year follow-up
|
3 years after surgery
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
The rate of R0-resection
Tidsramme: About 10 days after surgery
|
The proportion of patients undergoing radical resection in all surgical patients
|
About 10 days after surgery
|
The number of lymph node dissections and the positive
Tidsramme: About 10 days after surgery
|
The number of lymph node dissections and the positive
|
About 10 days after surgery
|
The duration of postoperative hospitalization
Tidsramme: Within 6 months after surgery
|
Time from end of surgery to discharge
|
Within 6 months after surgery
|
The incidences of early postoperative complications
Tidsramme: Within 30 days after surgery
|
The incidence of postoperative complications such as pneumonia, pleural effusion, anastomotic stenosis, anastomotic leakage, duodenal stump fistula, pancreatic fistula, abdominal abscess, and deep vein thrombosis (%).
|
Within 30 days after surgery
|
The incidence of perioperative mortality
Tidsramme: Within 30 days after surgery
|
The incidence of death due to the surgery
|
Within 30 days after surgery
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer efter sted
- Karcinom
- Neoplasmer, kirtel og epitel
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Gastrointestinale sygdomme
- Neoplasmer i hoved og hals
- Esophageale sygdomme
- Adenocarcinom
- Esophageale neoplasmer
Andre undersøgelses-id-numre
- S2AEG
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Adenocarcinom af Esophagogastric Junction
-
St. James's Hospital, IrelandUkendtBarrett Esophagus | Siewert Type II Adenocarcinoma af Esophagogastric Junction | Spiserørskræft | Siewert Type I Adenocarcinoma af Esophagogastric Junction | Siewert Type III Adenocarcinoma af Esophagogastric JunctionIrland
-
P. Herzen Moscow Oncology Research InstituteNational Medical Research Radiological Centre of the Ministry of Health...Ikke rekrutterer endnuSpiserørskræft | Spiserørskræft | Siewert Type I Adenocarcinoma af Esophagogastric Junction | Siewert Type III Adenocarcinoma af Esophagogastric JunctionDen Russiske Føderation
-
Jennifer Eva SelfridgeIkke rekrutterer endnuSiewert Type II Adenocarcinoma af Esophagogastric Junction | Adenocarcinom spiserør | Siewert Type I Adenocarcinoma af Esophagogastric Junction | Lokalt avanceret adenocarcinom
-
West China HospitalRekrutteringTilbagevenden | Neoplasmer i maven | Siewert Type II Adenocarcinoma af Esophagogastric Junction | Siewert Type III Adenocarcinoma af Esophagogastric JunctionKina
-
Guangdong Provincial Hospital of Traditional Chinese...RekrutteringSiewert Type II Adenocarcinoma af Esophagogastric Junction | Esophagogastric Junction AdenocarcinomKina
-
University of Kansas Medical CenterIkke rekrutterer endnuEsophagogastric Junction Disorder
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeKlinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk trin IV Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Uoperabelt Gastroøsofageal Junction Adenocarcinoma | Lokalt avanceret Gastroøsofageal Junction Adenocarcinoma | Postneoadjuverende terapi Stage III Gastroøsofageal... og andre forholdForenede Stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeEsophageal Adenocarcinom | Esophageal pladecellekarcinom | Klinisk trin III Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk fase II Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Klinisk fase IVA Gastroøsofageal Junction Adenocarcinoma AJCC v8 | Patologisk trin IIIA Gastroøsofageal... og andre forholdForenede Stater
-
Xijing Hospital of Digestive DiseasesFirst Affiliated Hospital Xi'an Jiaotong University; Henan Provincial People... og andre samarbejdspartnereRekrutteringSiewert Type II Adenocarcinoma af Esophagogastric JunctionKina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RekrutteringEsophagogastric Junction CarcinomKina
Kliniske forsøg med thoracoabdominal approach
-
Meshalkin Research Institute of Pathology of CirculationUkendtAortadissektion type B
-
Instituto de Cardiologia do Rio Grande do SulAfsluttetRespiratorisk komplikationBrasilien
-
University of the State of Santa CatarinaAfsluttetRespiratorisk terapi | Spædbørn med hjertesygdom | TeknikkerBrasilien
-
Vanderbilt University Medical CenterMedtronicAfsluttetThoracoabdominal aortaaneurismeForenede Stater
-
Lifetech Scientific (Shenzhen) Co., Ltd.RekrutteringThoracoabdominal; Aorta, Aneurisme, DissekereKina
-
Matthew EagletonMedtronic; NAMSA; Sanford HealthAktiv, ikke rekrutterendeThoracoabdominal aortaaneurismeForenede Stater
-
University Medical Center GroningenDutch Kidney Foundation; Amphia Hospital; Healthy.io Ltd.; E-Zorg B.V. / KPN... og andre samarbejdspartnereTilmelding efter invitation
-
The Christ HospitalMedtronicRekruttering
-
JOTEC GmbHAktiv, ikke rekrutterendeThoracoabdominal aneurismeTyskland
-
Lifetech Scientific (Shenzhen) Co., Ltd.RekrutteringThoracoabdominale aortaaneurismerKina